Adalimumab/certolizumab-pegolTuberculosis: 2 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2020年 / 1826卷 / 1期

关键词：

D O I：

10.1007/s40278-020-84467-8

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：20 / 20

相关论文

共 50 条

[31] Adalimumab/ustekinumabParadoxical vitiligo: 2 case reports
Reactions Weekly, 2018, 1714 (1) : 22 - 22
[32] Adalimumab/etanerceptDemyelinating disease: 2 case reports
Reactions Weekly, 2012, 1423 (1) : 5 - 5
[33] Adalimumab/vedolizumabKidney injury: 2 case reports
Reactions Weekly, 2024, 2021 (1) : 25 - 25
[34] Adalimumab/InfliximabAutoimmune Hepatitis: 2 case reports
Reactions Weekly, 2025, 2056 (1) : 29 - 29
[35] Adalimumab/azathioprine/infliximabLymphomas: 2 case reports
Reactions Weekly, 2012, 1391 (1) : 6 - 6
[36] Adalimumab/infliximabLack of efficacy: 2 case reports
Reactions Weekly, 2023, 1947 (1) : 22 - 22
[37] Adalimumab/infliximab/methotrexateGlomerulonephritis: 2 case reports
Reactions Weekly, 2021, 1884 (1) : 23 - 23
[38] Adalimumab/infliximabVarious toxicities: 2 case reports
Reactions Weekly, 2017, 1645 (1) : 22 - 22
[39] Adalimumab/secukinumab/ustekinumabPruritus: 2 case reports
Reactions Weekly, 2018, 1717 (1) : 20 - 20
[40] Adalimumab/infliximabPsoriasis and dspnoea: 2 case reports
Reactions Weekly, 2016, 1593 (1) : 18 - 18

← 1 2 3 4 5 →